Diligence memo · auto-generated · as of July 2, 2026
Artielle ImmunoTherapeutics Inc
Artielle ImmunoTherapeutics Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Artielle ImmunoTherapeutics Inc operates in Biotechnology, based in Tigard.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Artielle ImmunoTherapeutics Inc has raised $996K in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $710K on 2009-09-17.
Most recent recorded round closed around 2010-08-23.
Valuation (modeled)modeled
Provath models Artielle ImmunoTherapeutics Inc at approximately $5.5M (range $53K–$63M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.28× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 15.9 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 17% of Biotechnology peers (4293 compared).
Modeled value ranks above 11% of those peers.
Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.